Description

Shelter Pharma Limited's 861,000 equity shares issued at Rs. 42.25 per share on preferential basis pursuant to conversion of warrants are listed and permitted to trade from January 21, 2026.

Summary

Shelter Pharma Limited (Scrip Code: 543963) has listed 861,000 new equity shares on BSE effective January 21, 2026. These shares were issued to non-promoters on a preferential basis pursuant to conversion of warrants at Rs. 42.25 per share (face value Rs. 10, premium Rs. 32.25). The shares rank pari-passu with existing equity shares under ISIN INE013V01011.

Key Points

  • 861,000 equity shares of Rs. 10 face value issued at Rs. 42.25 per share
  • Allotment date: October 16, 2025
  • Trading commences: January 21, 2026
  • Issued to non-promoters on preferential basis pursuant to warrant conversion
  • Distinctive Numbers: 14001793 to 14862792
  • All shares subject to lock-in restrictions
  • Shares rank pari-passu with existing equity shares

Regulatory Changes

No regulatory changes. This is a standard listing notification for newly issued securities.

Compliance Requirements

Trading members must note the lock-in restrictions on these shares:

  • 336,000 shares (Dist. Nos. 14001793-14337792): Locked-in until August 14, 2026
  • 372,000 shares (Dist. Nos. 14337793-14709792): Locked-in until August 15, 2026
  • 153,000 shares (Dist. Nos. 14709793-14862792): Locked-in until August 14, 2026

Important Dates

  • Allotment Date: October 16, 2025
  • Trading Commencement: January 21, 2026
  • Lock-in Expiry: August 14-15, 2026 (varying by lot)

Impact Assessment

Limited market impact as this is a routine listing of preferential allotment shares. The 861,000 shares represent additional equity capital for Shelter Pharma Limited. All shares are subject to lock-in periods until August 2026, preventing immediate selling pressure. Trading members should be aware of the lock-in restrictions when processing orders for these distinctive numbers.

Impact Justification

Routine listing of equity shares from warrant conversion affecting a single company with lock-in restrictions, limited immediate market impact.